- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- What You Wear to the Office Still Matters
- Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE)
- Windows Ad Turns The Table On Apple

Oncothyreon: A Failed Drug Autopsy Performed By A Short Seller
Fund manager Martin Shkreli offers advice on how to avoid the next Oncothyreon blowup.
10:10AM 12/19/12

Nektar Therapeutics Is a Short
Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.
07:08AM 09/12/12